泛癌中 CCL18 的差异表达、预后及其与免疫细胞浸润的相关性分析

Analysis of differential expression, prognosis of CCL18 and itscorrelation with immune cell infiltration in pan-cancer

目的旨在通过多数据库的分析来揭示CCL18在33种癌症类型中的表达、预后及其与免疫细胞浸润的相关性。方法通过GTEx数据库、CCLE数据库、TCGA数据库综合分析CCL18在泛癌中的表达模式。单因素Cox回归用于分析CCL18在泛癌中的生存和预后。通过TIMER2.0数据库分析CCL18与免疫微环境的关系。分析了CCL18与免疫检查点基因表达谱、DNA错配修复基因(MMRs)和甲基转移酶编码基因的关系。Spearman用于分析CCL18表达水平与肿瘤突变负荷(TMB)和微卫星不稳定性(MSI)的关系。结果在本研究中,发现CCL18在大多数癌症中异常过表达。CCL18与肿瘤患者的年龄、性别、肿瘤分期和免疫亚型等临床参数密切相关。单因素回归分析表明CCL18表达与患者在ACC、DLBC、LAML、UVM、CESC和LGG中的不良预后密切相关。在大多数癌症中,CCL18的表达与28种免疫细胞亚型、免疫相关通路、肿瘤微环境呈正相关。CCL18与主要组织相容性复合体、免疫激活剂、免疫抑制剂、趋化因子和趋化因子受体相关基因共表达。此外,CCL18与许多癌症中的肿瘤新抗原、肿瘤突变负荷、微卫星不稳定性以及免疫检查点、错配修复和DNA甲基化转移酶相关基因的表达显著有关。GSEA分析表明CCL18表达显著富集了大多数肿瘤中的几种癌症相关通路和免疫相关通路。结论CCL18可能是确定癌症预后和免疫浸润的潜在分子生物标志物。

Objective To reveal the expression and prognosis of CCL18 in 33 cancer types and its association with immune cell infiltration through multi-database analysis.Methods The expression pattern of CCL18 in pan-cancer was analyzed using the GTEx database,CCLE database and TCGA database.Univariate Cox regression was used to analyze the survival and prognosis of CCL18 in pan-cancer.The relationship between CCL18 and the immune microenvironment was analyzed by TIMER 2.0 database.Moreover,the study examined the correlation between CCL18 and immune checkpoint gene expression profiles,DNA mismatch repair genes(MMRs)and methyltransferase coding genes.Spearman correlation was used to analyze the relationship between CCL18 expression levels and tumor mutation burden(TMB)and microsatellite instability(MSI).Results The study found that CCL18 was abnormally overexpressed in most cancers and closely related to clinical parameters such as age,gender,tumor stage and immune subtype.Univariate regression analysis showed that CCL18 expression was significantly associated with poor prognosis in ACC,DLBC,LAML,UVM,CESC,and LGG.Additionally,CCL18 expression showed positive correlations with 28 immune cell subtypes,immune-related pathways,and tumor microenvironment in most cancers.Then,it was found that CCL18 was co-expressed with major histocompatibility complex,immune activators,immunosuppressants,chemokines,and chemokine receptor-related genes.In addition,CCL18 was significantly associated with tumor neoantigens,tumor mutation load,microsatellite instability,and the expression of genes associated with immune checkpoints,mismatch repair,and DNA methyltransferase in various cancers.GSEA analysis showed that CCL18 expression was significantly enriched in several cancer-related and immune-related pathways in most tumors.Conclusion The findings suggest that CCL18 may serve as a potential molecular biomarker for cancer prognosis and immune infiltration.